Altimmune, Inc. (ALT) SEC filings

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30

$1.61−0.32 (-16.58%)

Close on Nov 12, 2026Market cap $313.17MP/E –Yield –

SEC filings

40 of Altimmune's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Oct 27, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 23, 2026	Oct 27, 2026	SEC EDGAR
Current report	8-K	Sep 24, 2026	Sep 29, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jul 28, 2026	Jul 28, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 16, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	Apr 22, 2026	Apr 24, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 16, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 16, 2026	Mar 17, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 6, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Feb 2, 2026	Feb 3, 2026	SEC EDGAR
Current report	8-K	Jan 27, 2026	Jan 28, 2026	SEC EDGAR
Current report	8-K	Dec 19, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Nov 30, 2025	Dec 1, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Oct 1, 2025	Oct 3, 2025	SEC EDGAR
Current report	8-K	Sep 25, 2025	Sep 25, 2025	SEC EDGAR
Proxy statement	DEF 14A	Sep 25, 2025	Aug 15, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 26, 2025	Jun 26, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	Mar 13, 2025	Mar 13, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 25, 2025	SEC EDGAR
Current report	8-K	Nov 15, 2024	Dec 11, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 11, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Sep 26, 2024	Sep 26, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Altimmune's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Sep 14, 2018
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALT.

Compare: ALT vs AVTX · ALT vs NTHI · ALT vs ADXN · ALT vs KZIA · ALT vs IXHL

Company	Revenue	Growth
ALT	$41.00K	+105.0%
AVTX	–	–
NTHI	–	–
ADXN	–	–
KZIA	–	–
IXHL	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 13
Held by institutions: 77.9%
Auditor: Ernst& Young LLP
SEC CIK: 1326190

Advertisement
300 × 250

See a number that looks wrong?